SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Gisela Hostenkamp, Frank R. Lichtenberg, The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence, Social Science & Medicine, 2015, 130, 162

    CrossRef

  2. 2
    Yandun Zou, Mingzhen Lin, Zhixin Sheng, Shaona Niu, Bortezomib and lenalidomide as front-line therapy for multiple myeloma, Leukemia & Lymphoma, 2014, 55, 9, 2024

    CrossRef

  3. 3
    Fortunato Morabito, Sara Bringhen, Alessandra Larocca, Pierre Wijermans, Maria Victoria Mateos, Peter Gimsing, Carla Mazzone, Daniela Gottardi, Paola Omedè, Sonja Zweegman, Juan José Lahuerta, Renato Zambello, Pellegrino Musto, Valeria Magarotto, Martijn Schaafsma, Albert Oriol, Gunnar Juliusson, Chiara Cerrato, Lucio Catalano, Massimo Gentile, Ana Isabel Turel, Anna Marina Liberati, Maide Cavalli, Davide Rossi, Roberto Passera, Stefano Rosso, Meral Beksac, Michele Cavo, Anders Waage, Jesus San Miguel, Mario Boccadoro, Pieter Sonneveld, Antonio Palumbo, Massimo Offidani, Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study, American Journal of Hematology, 2014, 89, 4
  4. 4
    Christoph Röllig, Stefan Knop, Martin Bornhäuser, Multiple myeloma, The Lancet, 2014,

    CrossRef

  5. 5
    Akira Matsumoto, Kazunori Kataoka, Yuji Miyahara, New directions in the design of phenylboronate-functionalized polymers for diagnostic and therapeutic applications, Polymer Journal, 2014, 46, 8, 483

    CrossRef

  6. 6
    Alessandra Romano, Annalisa Chiarenza, Concetta Conticello, Maide Cavalli, Calogero Vetro, Cosimo Di Raimondo, Rosario Cunsolo, Giuseppe Alberto Palumbo, Francesco Di Raimondo, Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients, European Journal of Haematology, 2014, 93, 3
  7. 7
    Alessandra Romano, Concetta Conticello, Francesco Di Raimondo, Bortezomib for the treatment of previously untreated multiple myeloma, Immunotherapy, 2013, 5, 4, 327

    CrossRef

  8. 8
    Branko Miladinovic, Rahul Mhaskar, Iztok Hozo, Ambuj Kumar, Helen Mahony, Benjamin Djulbegovic, Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error, Journal of Clinical Epidemiology, 2013, 66, 6, 654

    CrossRef

  9. 9
    Gareth J. Morgan, Faith E. Davies, Role of thalidomide in the treatment of patients with multiple myeloma, Critical Reviews in Oncology/Hematology, 2013, 88, S14

    CrossRef

  10. 10
    Branko Miladinovic, Ambuj Kumar, Iztok Hozo, Helen Mahony, Benjamin Djulbegovic, Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: A case study of meta-analyses of multiple myeloma trials, Contemporary Clinical Trials, 2013, 34, 2, 257

    CrossRef

  11. 11
    Laura Ciani, Sandra Ristori, Boron as a platform for new drug design, Expert Opinion on Drug Discovery, 2012, 1

    CrossRef

  12. 12
    Gregory A. Ellis, Michael J. Palte, Ronald T. Raines, Boronate-Mediated Biologic Delivery, Journal of the American Chemical Society, 2012, 134, 8, 3631

    CrossRef

  13. 13
    Lida Wang, Jingying Cui, Liping liu, Zhixin Sheng, Postrelapse survival rate correlates with first-line treatment strategy with thalidomide in patients with newly diagnosed multiple myeloma: a meta-analysis, Hematological Oncology, 2012, 30, 4
  14. 14
    Sarah Frankland-Searby, Sukesh R. Bhaumik, The 26S proteasome complex: An attractive target for cancer therapy, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2012, 1825, 1, 64

    CrossRef

  15. 15
    Sonia Vallet, Mathias Witzens-Harig, Dirk Jaeger, Klaus Podar, Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies, Expert Opinion on Pharmacotherapy, 2012, 13, 4, 473

    CrossRef

  16. 16
    Ivan Spicka, MV Mateos, K Redman, MA Dimopoulos, PG Richardson, An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation, Immunotherapy, 2011, 3, 9, 1033

    CrossRef

  17. 17
    Y Farnoushi, M Cipok, S Kay, H Jan, A Ohana, E Naparstek, R S Goldstein, V R Deutsch, Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos, British Journal of Cancer, 2011, 105, 11, 1708

    CrossRef

  18. 18
    Marta Krejci, Evzen Gregora, Jan Straub, Jiri Minarik, Vlastimil Scudla, Zdenek Adam, Andrea Krivanova, Ludek Pour, Lenka Zahradova, Tomas Buchler, Jiri Mayer, Roman Hajek, Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma, Annals of Hematology, 2011, 90, 12, 1441

    CrossRef

  19. 19
    Michelle de la Vega, James F. Burrows, James A. Johnston, Ubiquitination, Small GTPases, 2011, 2, 4, 192

    CrossRef

  20. 20
    Helen Georgiev, Ambuj Kumar, Rahul Mhaskar, Branko Miladinovic, Keith Wheatley, Benjamin Djulbegovic, Maintenance therapies for multiple myeloma, The Cochrane Library,